A phase Ib proof of concept trial of theliatinib in head and neck cancer
Latest Information Update: 21 Sep 2022
At a glance
- Drugs Xiliertinib (Primary)
- Indications Head and neck cancer
- Focus Proof of concept; Therapeutic Use
- 18 Aug 2016 New trial record
- 02 Aug 2016 According to a Chi-Med media release, this trial is expected to initiate by the end of 2016.